Effects of MS-8209, an Amphotericin B Derivative, on Tumor Necrosis Factor Alpha Synthesis and Human Immunodeficiency Virus Replication in Macrophages
AUTOR(ES)
Clayette, Pascal
FONTE
American Society for Microbiology
RESUMO
Amphotericin B derivatives, such as MS-8209, have been evaluated as a therapeutic approach to human immunodeficiency virus (HIV) infection. We show that MS-8209, like amphotericin B, increases tumor necrosis factor alpha (TNF-α) mRNA expression and TNF-α production and consequently HIV replication in human macrophages. These effects confirm the pharmacological risk associated with the administration of amphotericin B or its derivatives to HIV-infected patients.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=89691Documentos Relacionados
- MS-8209, a new amphotericin B derivative, provides enhanced efficacy in delaying hamster scrapie.
- Activity of MS-8209, a nonester amphotericin B derivative, in treatment of experimental systemic mycoses.
- Possible role of the V3 domain of gp120 in resistance to an amphotericin B derivative (MS8209) blocking human immunodeficiency virus entry.
- Reduction of NO Synthase Expression and Tumor Necrosis Factor Alpha Production in Macrophages by Amphotericin B Lipid Carriers
- Role of tumor necrosis factor alpha in activation and replication of the tat-defective human immunodeficiency virus type 1.